SP
BravenNow
Trial into puberty blockers for children paused over 'wellbeing concerns'
| United Kingdom | general | ✓ Verified - news.sky.com

Trial into puberty blockers for children paused over 'wellbeing concerns'

#puberty blockers #clinical trial #gender dysphoria #MHRA #King's College London #Cass Review #JK Rowling #children's wellbeing

📌 Key Takeaways

  • UK government pauses puberty blocker trial over wellbeing concerns
  • MHRA raised new concerns directly related to children's wellbeing
  • Recruitment postponed until safety and necessity are confirmed
  • Trial aimed to study effects on 226 young people aged 10-16
  • Controversy includes legal action by JK Rowling and criticism from Conservative leader Kemi Badenoch

📖 Full Retelling

The UK government has paused a clinical trial into puberty blockers for children after the Medicines and Healthcare products Regulatory Agency raised new concerns directly related to the wellbeing of young people, a spokesperson announced on Saturday 21 February 2026, following legal action by campaigners including Harry Potter author JK Rowling against the study. The Pathways trial, led by researchers at King's College London, had aimed to recruit 226 young people aged between 10 and almost 16 to study the effects of puberty blockers on children with gender dysphoria. According to the Department of Health and Social Care, recruitment to the study will remain postponed until concerns are resolved with King's College and it is concluded that the trial is 'both safe and necessary.' The pause comes amid significant controversy surrounding the use of puberty blockers, with JK Rowling previously describing the trial as 'an unethical experiment on children who can't give meaningful consent,' while Conservative leader Kemi Badenoch had called for the trial to be stopped 'before more damage is done to children.' Health Secretary Wes Streeting, who admitted being 'uncomfortable' with puberty blockers being given to children, defended the decision to proceed with the trial as 'the right thing to do,' citing his responsibility to follow expert advice.

🏷️ Themes

Medical Ethics, Gender Identity, Child Healthcare, Research Regulation

📚 Related People & Topics

Cass Review

Cass Review

Review of gender identity services in England

The Independent Review of Gender Identity Services for Children and Young People (commonly referred to as the Cass Review) is an independent review commissioned in 2020 by NHS England and NHS Improvement and led by Hilary Cass, a retired consultant paediatrician and the former president of the Royal...

View Profile → Wikipedia ↗

MHRA

Topics referred to by the same term

MHRA may refer to:

View Profile → Wikipedia ↗
J. K. Rowling

J. K. Rowling

British author (born 1965)

Joanne Rowling ( ROH-ling; born 31 July 1965), better known by her pen name J. K. Rowling, is a British author, philanthropist, producer, and screenwriter. She is best known for writing Harry Potter, a seven-volume series about a young wizard. Published from 1997 to 2007, the fantasy novels are the...

View Profile → Wikipedia ↗

Entity Intersection Graph

No entity connections available yet for this article.

Deep Analysis

Why It Matters

The pause of the puberty blockers trial highlights concerns over child wellbeing and the need for rigorous evidence before medical interventions. It underscores the tension between urgent gender care needs and regulatory safety standards.

Context & Background

  • The trial, led by King's College London, aimed to recruit 226 children aged 10-16 to study puberty blockers.
  • The Medicines and Healthcare products Regulatory Agency raised new wellbeing concerns prompting the pause.
  • The trial was based on the Cass Review, which found existing research on puberty blockers to be poor.

What Happens Next

Recruitment will resume only after the MHRA and clinical leaders resolve the concerns with the sponsor. The trial will undergo further scientific review to ensure safety and efficacy before restarting.

Frequently Asked Questions

Why was the trial paused?

Because the MHRA raised new concerns directly related to the wellbeing of children involved in the study.

Who is conducting the trial?

Researchers at King's College London are leading the Pathways trial.

What are the next steps for the trial?

The trial will be postponed until the issues are resolved and further scientific dialogue takes place.

Original Source
Trial into puberty blockers for children paused over 'wellbeing concerns' Recruitment to the study will be postponed until the issues have been resolved with the sponsor, King's College, and it is concluded that it is "both safe and necessary", a spokesperson for the Department of Health and Social Care. Saturday 21 February 2026 05:47, UK Why you can trust Sky News A clinical trial into puberty blockers has been paused after the medicines regulator raised "new concerns directly related to the wellbeing of children", the government said. It comes after campaigners, including Harry Potter author JK Rowling, launched legal action against the government over the trial, which Ms Rowling described as "an unethical experiment on children who can't give meaningful consent". Announcing the pause, a spokesperson for the Department of Health and Social Care said the Medicines and Healthcare products Regulatory Agency has raised "new concerns - directly related to the wellbeing of children and young people - and scientific dialogue will now follow with the trial sponsor". "As the evidence is now being interrogated by clinicians, preparations for the trial have been paused while the MHRA and clinical leaders work through these concerns," the spokesperson said. Researchers at King's College London, who were set to lead the Pathways trial, previously said they were aiming to recruit around 226 young people aged between 10 and almost 16. Be the first to get Breaking News Install the Sky News app for free Recruitment to the study will be postponed until the issues have been resolved with the sponsor, King's College, and it is concluded that it is "both safe and necessary", the department spokesperson said. A spokesperson for King's College said: "The wellbeing and health of young people with gender incongruence and their families has been, and will remain, our priority, and we will continue to work with the MHRA to support their further review of the trial, which has been designed ...
Read full article at source

Source

news.sky.com

More from United Kingdom

News from Other Countries

🇺🇸 USA

🇺🇦 Ukraine